How Are You Feeling? Who Wants To Know? Patients’ and Oncologists’ Preferences for Discussing Health-Related Quality-of-Life Issues

Detmar, Symone; Aaronson, Neil K.; Wever, Lieke; Müller, Martin; Schornagel, J. H.

doi:10.1200/jco.2000.18.18.3295

Cited by 306 publications

(213 citation statements)

References 34 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…One of the greatest barriers to effective palliative care is poor communication between patients, their caregivers, and health care providers [12][13][14]. A principal reason for initiation of hospice care is the need for expert pain and symptom management.…”

Section: Introductionmentioning

confidence: 99%

Barriers to Pain Management: Caregiver Perceptions and Pain Talk by Hospice Interdisciplinary Teams

Oliver

Wittenberg-Lyles

Demiris

et al. 2008

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

As patients are cared for in their home by family caregivers, several challenges arise in effective pain and symptom management. Despite hospice's reputation as the gold standard for terminal care, there is still a need to improve pain management practices including challenges that caregivers face, related to pain assessment, reluctance and fear of administering medication, noncompliance with pain medicine regimens, and hesitance to report pain. The hospice philosophy of care promotes service for both patients and their family by an interdisciplinary team, and total pain management is a goal of this care. The aim of this control phase of a larger National Cancer Institute-funded mixed methods study was to understand the current practice of hospice assessment and collaboration on informal caregiver issues related to pain management. This study of 30 hospice caregiver/patient dyads from one rural hospice found that 87% of caregivers indicated concern with at least one question on the Caregiver Pain Medicine Questionnaire (CPMQ). Interdisciplinary team discussions for 23 of the dyads were recorded over nine months for a total of 86 sessions. Although caregiver concerns were identified with the CPMQ by the research team, there was only one discussion of caregiver pain related concerns during the hospice team meeting. This despite the finding that 38% of the time involved in a patient discussion is spent on pain related talk. These findings indicate an opportunity for improvement by hospice teams through focusing on caregiver assessment and intervention.

show abstract

Section: Introductionmentioning

confidence: 99%

Barriers to Pain Management: Caregiver Perceptions and Pain Talk by Hospice Interdisciplinary Teams

Oliver

Wittenberg-Lyles

Demiris

et al. 2008

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

show abstract

“…Moreover, patients sometimes are reluctant to disclose their psychological concerns spontaneously, and they leave the initiative of discussing these topics to their physician. 16 It has been reported that distress in older patients is more difficult to detect, because elderly patients tend to show less overt symptoms of distress and often are more reluctant to talk explicitly about problems with emotional functioning. 17 Therefore, physicians need to be able to investigate those concerns explicitly by eliciting patients' disclosure and by clarifying expressed concerns.…”

Section: Discussionmentioning

confidence: 99%

Factors that influence physicians' detection of distress in patients with cancer

Merckaert

Libert

Delvaux

et al. 2005

Cancer

View full text Add to dashboard Cite

Objective In vitro observations and studies in murine experimental autoimmune encephalomyelitis (EAE) have shown protective effects of sodium channel blockers on central nervous system axons and improved clinical status when treatment is continued throughout the period of observation. Several clinical studies of sodium channel blockers are under way in patients with multiple sclerosis. Here we asked whether a protective effect would persist after withdrawal of a sodium channel blocker. Methods We studied a mouse model of myelin oligodendrocyte glycoprotein–induced EAE treated with phenytoin or carbamazepine. Results Both phenytoin and carbamazepine significantly improved the clinical course of the disease. Withdrawal of phenytoin resulted in acute exacerbation, accompanied by a significantly increased inflammatory infiltrate within the central nervous system and the death of nearly 60% of EAE mice. There were no clinical worsening or deaths in control mice after withdrawal of phenytoin. Withdrawal of carbamazepine led to acute worsening of EAE symptoms, increased inflammatory infiltrate, and was associated with the death of 8% of mice. Interpretation These results, together with results showing effects of sodium channel blockers in immune cells, raise questions about the long‐term effects of sodium channel blockers in neuroinflammatory disorders, and suggest that clinical studies of sodium channel blockers in these disorders should be planned carefully. Ann Neurol 2007

show abstract

“…18 Lokalizasyonu nedeniyle hızlı bir tedavi süreci gerektiren, nörolojik fonksiyonlarda yetersizliklere neden olan, hastalık sürecinde bireyin rehabilitasyonunda özel bir çaba gerektiren beyin tümörü, hasta ve ailesinin yaşam kalitesini olumsuz etkileyen ilerleyici bir hastalıktır. 4 Özellikle sinir sistemini etkileyen genetik kaynaklı kalıtsal hastalıklar ve duyu sisteminin bozuklukları; potasyum kanallarının genlerinde meydana gelen mutasyonlara bağlı olarak ortaya çıkmakta-dır.…”

Section: şEki̇lunclassified

Investigation of Serum Levels of Inwardly Rectifying and Two-Pore Potassium Channel Proteins in Benign and Malign Brain Tumors

Sari¹,

Kılıç²,

Kurt³

et al. 2016

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Ö ÖZ ZE ET T A Am ma aç ç: : Bu çalışmada, iyi huylu ve kötü huylu beyin tümörü olan hasta serumlarında, içeri doğru düzeltici potasyum kanalı (KCNJ3) ve iki gözenekli potasyum kanalı (KCNK9) protein dü-zeylerindeki değişikliklerin araştırılması amaçlanmıştır. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışma için 3 grup oluşturulmuştur: grup-1; sağlıklı gönüllülerden oluşan kontrol grubu, grup-2; iyi huylu beyin tü-mörü olan hasta grubu, grup-3; kötü huylu beyin tümörü olan hasta grubu. 50 kişiden oluşan hasta grubu ve 25 kişiden oluşan kontrol grubu olmak üzere tüm katılımcılarda, serumda KCNJ3 ve KCNK9 protein düzeyleri ELISA yöntemi ile ölçülmüştür. B Bu ul lg gu ul la ar r: : Çalışmaya dahil edilen tüm katılımcılar, KCNJ3 ve KCNK9 proteinleri açısından değerlendirildiğinde; sağlıklı gönüllülerden oluşan kontrol grubu ile iyi huylu beyin tümörü olan hasta grubu arasında anlamlı bir fark bulunamamıştır (p>0,05). Öte yandan kötü huylu beyin tümörü olan hasta grubunda, hem sağlıklı gö-nüllülerden oluşan kontrol grubu hem de iyi huylu beyin tümörü olan hasta grubuna göre, KCNJ3 ve KCNK9 proteinlerinin anlamlı olarak arttığı gözlenmiştir (p<0,05). S So on nu uç ç: : KCNJ3 ve KCNK9 proteinlerinin kötü huylu beyin tümörü olan hasta grubunda artması, bu proteinlerin beyin tü-mörlerinin tanısında kullanılabileceğini ve bu alanda yapılacak yeni çalışmalara da yön verebileceğini düşündürmektedir.A An na ah ht ta ar r K Ke el li im me el le er r: : Neoplaziler; beyin neoplazileri; potasyum kanalları; KCNJ3 protein, insan; KCNK9 protein, insan A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : In this study, it was aimed to investigate the variations affecting the tumor invasion in inwardly rectifying potassium channel (KCNJ3) and two-pore potassium channel proteins (KCNK9) in serums of benign and malign brain tumor patients. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Three study groups were formed: Group-1: control group of healthy volunteers, group-2: patients group with benign brain tumor and group-3: patients group with malign brain tumor. Serum protein levels of KCNJ3 ve KCNK9 were determined with ELISA method for all participants including the group of patients of 50 people and the control group of 25 people. R Re es su ul lt ts s: : There was no significant difference for serum levels of KCNJ3 and KCNK9 proteins between the control group of healthy volunteers and the patients group with benign brain tumors (p>0,05). However it was observed that the serum levels of KCNJ3 and KCNK9 proteins significantly increased in cases with malignant brain tumors compared to the ones with benign brain tumors and the control group of healthy volunteers (p<0,05). C Co on nc cl lu us si io on n: : We can conclude that KCNJ3 and KCNK9 protein levels can be used in diagnosis of brain tumors due to the increased serum levels in malignant brain tumors. It is expected that this study would give a direction to new researches on this topic.K Ke ey y W Wo or rd ds s: : Neoplasms; brain neoplasms; potassium...

show abstract

How Are You Feeling? Who Wants To Know? Patients’ and Oncologists’ Preferences for Discussing Health-Related Quality-of-Life Issues

Abstract: Although both patients and oncologists seem willing to discuss a wide range of HRQL issues, communication regarding psychosocial issues may be hampered by competing expectations as to who should take the lead in initiating such discussions.

Cited by 306 publications

References 34 publications

Barriers to Pain Management: Caregiver Perceptions and Pain Talk by Hospice Interdisciplinary Teams

Barriers to Pain Management: Caregiver Perceptions and Pain Talk by Hospice Interdisciplinary Teams

Factors that influence physicians' detection of distress in patients with cancer

Investigation of Serum Levels of Inwardly Rectifying and Two-Pore Potassium Channel Proteins in Benign and Malign Brain Tumors

Contact Info

Product

Resources

About